Pluvicto for prostate cancer with kidney or marrow issues
Part of Blood & lymphatic, Cancer, Kidney & urinary clinical trials.
This trial studies how well a radioactive drug called Pluvicto works in men with prostate cancer who also have kidney or bone marrow problems. You'll get the treatment and have several scans to see how the drug affects your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be approved for Pluvicto therapy (a radioactive treatment for prostate cancer).
- You must have kidney problems (GFR between 30 and 50) or low blood counts (low white blood cells or platelets).
- You must be willing to have multiple imaging scans during the study.
- This trial is for men with prostate cancer (women and children are not eligible).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This study looks at how well a drug called Pluvicto (Lu-PSMA-617) works in real life for men with advanced prostate cancer that has stopped responding to hormone therapy. It helps doctors understand how long people live after treatment.
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
This study uses special scans to see how well the drug Pluvicto is working in men with metastatic prostate cancer. You would have two PET scans, one before starting treatment and one after 12 weeks, to check your cancer's response.
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
Hear when a new Lu-177 PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.